Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115198) titled 'Real-world effectiveness and safety of upadacitinib in difficult-to-treat Crohn's disease: a multicenter study in China' on Dec. 23, 2025.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Condition:
Difficult-to-treat CD,DTT-CD
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2025-12-01
Target Sample Size: Observation group:115;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=298504
Published by HT Digital Content Services with permission ...